Document is current
Any future updates will be listed below
-
Authors
Bae, Jooeun https://orcid.org/0000-0002-8922-9703
Accardi, Fabrizio
Hideshima, Teru
Tai, Yu-Tzu https://orcid.org/0000-0001-6199-3569
Prabhala, Rao
Shambley, Aaron
Wen, Kenneth
Rowell, Sean
Richardson, Paul G. https://orcid.org/0000-0002-7426-8865
Munshi, Nikhil C. https://orcid.org/0000-0002-7344-9795
Anderson, Kenneth C. https://orcid.org/0000-0002-6418-0886
- License Information
-
More Information
Article History
Received: 3 November 2020
Revised: 29 April 2021
Accepted: 13 May 2021
First Online: 21 July 2021
Compliance with ethical standards
:
: KCA is an advisor/consultant for Bristol Myers Squibb, Janssen, Pfizer, Amgen, AstraZeneca, OncoPep, and Precision Biosciences, and is a scientific founder of C4 therapeutics and OncoPep. NCM is in consultant/advisory board for Bristol Myers Squibb, Takeda, Janssen, AbbVie, Karyopharm, Adaptive, OncoPep, and Amgen, and is a scientific founder of OncoPep. PGR has research support from Bristol Myers Squibb, research support and honoraria (advisory committee member) from Oncopeptides, Celgene, Takeda, and Karyopharm, and honoraria (advisory committee member) from Janssen, Sanofi, and Secura Bio outside the submitted work. JB is in advisory board and a scientific founder of OncoPep. No relevant conflicts of interest were disclosed by the other authors.
